Prospective multicenter study demonstrates plasma p-tau217's effectiveness in diagnosing beta-amyloid status, suggesting broad clinical applications.
In a real-world multicenter memory-clinic cohort, plasma p-tau217 measured on a fully automated platform accurately discriminated CSF Aβ status and enabled reliable rule-in/rule-out classification in over half of patients. These findings support its broader clinical use as an initial diagnostic tool for AD.
No takes yet. Share an insight, caveat, or question.
Massons et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: